About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

Not Yet RecruitingNANCT07628699

Digital Heart Rate Variability Biofeedback Intervention for First Episode Psychosis

The objective of the current study is to assess the impact of a five-week digital heart rate variability biofeedback (HRV-B) intervention or music listening on the well-being of first episode psychosi...

Lead sponsor: The University of Hong Kong•1 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Contacts

Sherry Kit Wa Chan, PhD

CONTACT

+(852) 2255 3064 kwsherry@hku.hk

Sophia M Vann-Adibe, Bachelors of Science

CONTACT

+85253249444 svann@hku.hk

Sponsors

Lead Sponsor

The University of Hong Kong

Age

18 - 55 years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Patients with first-episode-psychosis who have been in treatment for less than 5 years
•Inclusive of affective and non-affective psychosis
•Aged 18-55
•A diagnosis of schizophrenia-spectrum disorders or affective psychosis including schizoaffective disorder, bipolar affective disorders and depression with psychosis based on DSM V diagnostic criteria
•Able to provide written informed consent.
•Patients should be stable but with symptoms present
•Score a minimum of 7 on the Calgary Depression Scale.

Exclusion Criteria

•Any organic neurological or cardiac conditions
•Prescription of cardiovascular medication
•Active severe suicidal ideation
•Diabetes as this can affect HRV
•Current substance abuse
•An ECG will be performed on each participant prior to joining the study to exclude undiagnosed cardiac conditions

Related studies

Nursing Intervention in Weight and Metabolic Syndrome Management in First-episode Psychosis (MetaKOP)

NCT06650943 · First Episode Psychosis (FEP), Metabolic Syndrome X

Enrolling By InvitationNA

California Collaborative Network to Promote Data Driven Care and Improve Outcomes in Early Psychosis

NCT04007510 · First Episode Psychosis (FEP)

Enrolling By InvitationNA

Reducing the Duration of Untreated Psychosis in the United States: The Impact of Screening and Systematic Communication

NCT05509998 · First Episode Psychosis (FEP), Clinical High Risk for Psychosis (CHR)

Not Yet RecruitingNA

Early Psychosis: Investigating Cognition

NCT07196423 · First Episode Psychosis (FEP), Psychosis

Not Yet RecruitingNA

Testing the Efficacy of the Cannabis Clinic for Patients With Psychosis (CCP) Intervention for Cannabis Use Reduction/Cessation in Patients With First Episode Psychosis (FEP)

NCT07245212 · Psychosis, Cannabis Use Disorder, and more

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: June 5, 2026Terms

Trial snapshot

StatusNOT_YET_RECRUITING

PhaseNA

Enrollment80

Start dateJun 2026

Last updatedJun 5, 2026

Condition

First Episode Psychosis (FEP)

Locations shown

Queen Mary Hospital/University of Hong Kong

Hong Kong, SAR China

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: June 5, 2026Data synced to Clareo: June 28, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions